Thalidomide for patients with severe autoimmune disease or autoinflammatory disease

Thalidomide for patients with severe autoimmune disease or autoinflammatory disease - Thalidomide for patients with severe autoimmune disease or autoinflammatory disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034534

Enrollment

Registered

2018-10-17

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe autoimmune disease or autoinflammatory disease who was refractory against standard treatment

Interventions

Thalidomide 50-400mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Registance against standerd treatment or steroid-dependent 2. No experience of thalidomide 3. Patients gave written informed consent

Exclusion criteria

Exclusion criteria: 1. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2. Infection of HIV, HCV or HBV 3. Administraion of live vaccine within 4 weeks 4. Pregnant subjects or subjects who do not agree with contraception during the study period 5. Others

Design outcomes

Primary

Measure	Time frame
inhibition of disease activity	—

Secondary

Measure	Time frame
improvement of physician's VAS, patient's VAS, biomarkers of disease activity and dose of corticosteroids	—

Countries

Japan

Contacts

Public ContactKenichi Nishimura

Yokohama City University Hospital Department of Pediatrics

k_nsm@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026